Contrasting Interpace Biosciences (OTCMKTS:IDXG) & InfuSystem (NYSE:INFU)

InfuSystem (NYSE:INFU) and Interpace Biosciences (OTCMKTS:IDXG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk & Volatility

InfuSystem has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Profitability

This table compares InfuSystem and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Interpace Biosciences	65.25%	219.07%	105.05%

Valuation and Earnings

This table compares InfuSystem and Interpace Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40 million	1.31	$870,000.00	$0.38	24.34
Interpace Biosciences	$38.73 million	0.21	$24.58 million	($0.05)	-36.00

Interpace Biosciences has lower revenue, but higher earnings than InfuSystem. Interpace Biosciences is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 5.5% of Interpace Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for InfuSystem and Interpace Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	1	2	0	2.67
Interpace Biosciences	0	0	0	0	0.00

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 62.16%. Given InfuSystem’s stronger consensus rating and higher probable upside, equities research analysts plainly believe InfuSystem is more favorable than Interpace Biosciences.

Summary

InfuSystem beats Interpace Biosciences on 10 of the 14 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.